SeekingAlpha · Mar 6, 2026
RC
NASDAQ · RCKT
Rocket Pharmaceuticals, Inc.
Healthcare · Biotechnology
$3.50
Down-$0.13 (-3.71%)
Updated Sep 18, 2026, 9:06 PM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 372.83M
- P/E ratio
- -1.6
- Dividend yield
- 0.00%
- 52-week range
- $2.53 – $5.45
- Volume
- 1.86M
- Avg. volume
- 2.37M
Price performance
RCKT price history
1M range · 0 trading sessions · Daily adjusted prices
RCKT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest RCKT news
The latest Smart Investors Daily articles mentioning RCKT.
Stock researchCompany · Overview
RCKT research
Overview
Company profile and research snapshot.
Company profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | Needham | Buy | — |
| Sep 16, 2026 | Wedbush | Outperform | — |
| Sep 15, 2026 | Chardan Capital | Buy | — |
| Sep 1, 2026 | Chardan Capital | Buy | — |
| Aug 11, 2026 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 2, 2026
Goldman Sachs Maintains Sell on Rocket Pharmaceuticals, Raises Price Target to $3
Goldman Sachs analyst Richard Law maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Sell and raises the price target from $2 to $3.
Benzinga · Feb 27, 2026
Rocket Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 EPS results. Also, Cantor Fitzgerald raised its price target on the stock from $8 to $10.
Benzinga · Feb 27, 2026
Cantor Fitzgerald Maintains Overweight on Rocket Pharmaceuticals, Raises Price Target to $10
Cantor Fitzgerald analyst Josh Schimmer maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Overweight and raises the price target from $8 to $10.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
